Clinical trials: B-Cell Non-Hodgkin Lymphoma-Recurrent
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
This study aims to provide a basis for further clinical development of YK012.
- Trial name
- NCT06565689
- Testing
- YK012
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Excyte Biopharma Ltd
Lymphoma
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00033423
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lymphoma
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells.
- Trial name
- NCT00057954
- Testing
- Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI)
- Where
- 19 sites in United States
- Volunteers
- 6 people
- Sponsor
- Eastern Cooperative Oncology Group
Relapsed or Refractory Large B-cell Lymphoma
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy.
- Trial name
- NCT07479797
- Testing
- KITE-753, Axicabtagene Ciloleucel, Fludarabine
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 550 people
- Sponsor
- Kite, A Gilead Company
Lymphoma
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as carmustine, etoposide, cytarabine, and melphalan work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00244946
- Testing
- therapeutic autologous lymphocytes, carmustine, cytarabine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00387959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00278161
- Testing
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
This single-arm, multicenter Phase 2 study will treat the patients who have Recurrent or refractory diffuse large B cell lymphoma with an infusion of the patient's own T cells that have been genetically modified to express a…
- Trial name
- EECBL (NCT02728882)
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
Lymphoma
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer…
- Trial name
- NCT00863369
- Testing
- rituximab, bortezomib, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
This phase I/II trial finds the highest safe dose of IMGN632 that can be given with other chemotherapy without causing severe side effects, studies what kind of side effects IMGN632 may cause, and determines whether IMGN632 is a…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent T Acute Lymphoblastic Leukemia
- Trial name
- NCT05320380
- Testing
- Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine
- Sponsor
- Children's Oncology Group
Leukemia, Lymphoma
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus.
- Trial name
- NCT00002956
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma
Q702 for the Treatment of Patients With Hematologic Malignancies
This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06712810
- Testing
- Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Mayo Clinic
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.
Leukemia, Lymphoma
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00044954
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- 14 sites in United States
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
- Trial name
- NCT03808610
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00042913
- Testing
- epratuzumab
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL)
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with…
- Conditions
- Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL), CNS Lymphoma
- Trial name
- NCT05098613
- Testing
- CD19x22 CAR T Cells
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
Diffuse Large B Cell Lymphoma
A Study of ICP-022 in Patients With R/R DLBCL
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL.
- Trial name
- DLBCL (NCT04438005)
- Testing
- ICP-022
- Where
- 7 sites in China
- Volunteers
- 3 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy before a donor umbilical cord blood transplant (UCBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT01093586
- Testing
- double-unit umbilical cord blood transplantation, cytogenetic analysis, bone marrow aspiration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.